As we approach the end of 2025 and prepare to slow down for the holidays, I want to take a moment to reflect on an exceptional year for Medaffcon—one defined by growth and expansion.
Thanks to the dedication of our talented team and the trust of our clients, the year has been nothing short of record-breaking. While numbers alone never tell the full story, they do reflect the value we continue to create in the Nordics through science, insight, and collaboration.
One of the defining milestones of the year was Medaffcon joining the Pharma Industry Finland (PIF) community. We are honored to have had Jarmo Hahl elected to the PIF Board, marking an important step in deepening our influence on the future of the pharmaceutical ecosystem in Finland. This recognition reinforces our long-standing commitment to evidence-based decision-making, responsible use of real-world data, and advancing patient access to impactful treatments.
In 2025, we also reached a new level in scientific output and visibility:
These achievements reflect the exceptional scientific professionalism our teams bring to every partnership.
This year also marked the launch of our first international EMMA event—a proud moment for our entire organization. While we see opportunities for fine-tuning the newly international concept, the positive reception and strong participation reaffirm our belief in the long-term value and possibilities of this platform.
Our Swedish team continued its strong growth as well, thriving in the inspiring environment of Forskaren, Stockholm’s hub for health innovation. The enthusiasm and momentum within the Swedish organization signal a bright future for our Nordic footprint.
As we enter 2026, our mission remains unchanged: to deliver high-quality scientific insight that enables better decisions, better care, and better outcomes. But this year has expanded our horizons—we are thinking bigger, contributing more boldly, and growing faster than ever before.
I want to extend my heartfelt thanks to the entire Medaffcon team for their passion and dedication, to our clients for their trust and partnership, and to our collaborators across the life sciences community for inspiring us every day.
Wishing all of you a peaceful Christmas season and a successful, healthy year ahead.
Warm regards,
Heikki Koski
CEO, Medaffcon
The conference explores how real-world data (RWD) and artificial intelligence (AI) can transform drug development, regulatory and HTA decision-making, and ultimately drive value-based, patient-focused healthcare.
The membership offers a broader view of industry developments and supports the company’s work to advance sustainable healthcare.
Finland is moving toward the European Health Data Space (EHDS) with strong national systems, but local readiness, funding, and interoperability remain challenges.